anonymous
Guest
anonymous
Guest
Let’s be honest—-/
The company survey SHOULD bring to surface a lot of issues in the company. Yet, IT WON’T.
The timing alone should yield low ratings due to the low value of the stock, and for many PHARMA people the shifting of territories and changes to the portfolio.
I know they want high participation but with the results I hear the output should be unbelievably poor. I am curious to see how they manipulate the results.
The company survey SHOULD bring to surface a lot of issues in the company. Yet, IT WON’T.
The timing alone should yield low ratings due to the low value of the stock, and for many PHARMA people the shifting of territories and changes to the portfolio.
I know they want high participation but with the results I hear the output should be unbelievably poor. I am curious to see how they manipulate the results.